Increased Risk of Herpes Zoster in Diabetic Patients Comorbid with Coronary Artery Disease and Microvascular Disorders: A Population-Based Study in Taiwan

Chi-Chen Ke¹, Hui-Chin Lai¹, Ching-Heng Lin², Chih-Jen Hung¹, Der-Yuan Chen³, Wayne H-H. Sheu⁴, Ping-Wing Lui¹,²,⁵ *

¹ Department of Anesthesiology, Taichung Veterans General Hospital, Taichung, Taiwan, ² Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, ³ Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ⁴ Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ⁵ Institute of Pharmacology, National Yang Ming University, Taipei, Taiwan

* superanesthesia@gmail.com

Abstract

We investigated the association between the risk of herpes zoster (HZ) and diabetes-related macrovascular comorbidities and microvascular disorders in diabetic patients. This retrospective study included 25,345 patients with newly identified HZ and age- and gender-matched controls retrieved from the National Health Insurance Research Database in Taiwan during the period of 2005 to 2011. Multivariate logistic regression analyses were used to calculate the odds ratios (OR) and to assess the risk factors for HZ in diabetic patients with associated macrovascular or microvascular disorders. Risk factors for HZ were significantly increased in cases of diabetes mellitus (DM) compared with those in cases of non-DM controls (20.2% vs. 17.0%, OR = 1.24, p < 0.001). Results of age- and gender-adjusted analyses demonstrated a significantly higher risk of HZ in DM patients with accompanying coronary artery disease (CAD) (adjusted OR = 1.21, p<0.001) and microvascular disorders (aOR = 1.32, p<0.001) than in DM patients with other comorbidities but no microvascular disorders. Patients who took thiazolidinedione, alpha-glucosidase inhibitors and insulin had a higher HZ risk than those taking metformin or sulphonylureas alone (aOR = 1.11, 1.14 and 1.18, p<0.001, respectively). Patients who took insulin alone or in combination with other antidiabetic agents had a significantly higher risk of HZ (aOR = 1.25, p<0.001) than those who received monotherapy. Diabetic patients comorbid with coronary artery disease and associated microvascular disorders had an increased risk of HZ occurrence.
Introduction

Herpes zoster (HZ) is caused by the reactivation of varicella-zoster virus (VZV) latent in the sensory ganglia after primary infection. It is a painful blister or rash on the afflicted dermatomes secondary to the spreading of the virus along the sensory nerve fibers [1–3]. The annual incidence rate of HZ is similar to that in North America, Europe and the Asia-Pacific region, ranging from 3–5 cases per 1000 person-years (PY). The incidence of HZ substantially increases with age and immunosuppression, affecting more than 50% of subjects aged >85 years [4].

Diabetic patients are susceptible to HZ secondary to VZV reactivation as cell-mediated immunity (CMI) declines during the process [5]. Diabetes mellitus (DM) is commonly regarded as a prothrombotic disorder associated with altered innate or adaptive immunity and endothelium dysfunction secondary to inflammation [6]. Thus, patients with DM have accompanying chronic comorbid diseases or related vascular complications, which are considered a major preventable risk factor for cardiovascular diseases. Diabetic patients are 2 to 4 times more likely to develop cardiovascular or cerebrovascular diseases than non-diabetic patients [7–9]. When patients have two or more coexisting comorbidities, there is an increased risk of HZ occurrence [10]. On the other hand, a retrospective cohort study in the UK demonstrated that HZ was an independent risk factor for VZV vasculopathy such as stroke, transient ischemic attack and myocardial infarction [11]. However, few studies have explored the association between the risk of HZ in diabetic patients comorbid with coronary artery diseases (CAD) and diabetes-related microvascular disorders.

The objectives of this study were to determine whether the risk of HZ occurrence would be escalated in diabetic patients comorbid with coronary artery diseases or in combination with other related microvascular disorders. In addition, using data retrieved from a nationwide database in Taiwan, we assessed the impact of anti-diabetic agents on the risk of HZ in these patients.

Materials and Methods

Data source

Since 1995, the National Health Insurance program has provided comprehensive medical coverage to 99% of the population of 23 million in Taiwan. The National Health Research Institutes (NHRI) have established a National Health Insurance Research Database (NHIRD). All medical records, including demographic characteristics, underlying comorbidities, as well as the date of the first outpatient visit, inpatient admission and discharge, and disease status at discharge, are made available in anonymous format for research purposes. The NHIRD also provides information about inpatient and outpatient use of medical services for all beneficiaries. Patients diagnosed with HZ were identified through claims data of the NHIRD by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes, which were used to define diseases. As the NHRI made the claim data available in an anonymous format which provided the individuals cannot be identified individually, the retrospective studies do not need the ethical approval from ethics committees in Taiwan.

Collection of cases and controls

In this population-based retrospective case control study, we used a systemic sampling of patient data from a total of 1,000,000 subjects, which was released by the NHIRD (Fig 1). Data on a total of 25,345 patients aged ≥18 years with newly identified HZ (ICD-9-CM code 053) were retrieved from the claims database during the period of 2005 to 2011. The inclusion criteria for data retrieval were: patients with the principal diagnosis of HZ who visited an outpatient...
department at least twice or those who were admitted to the hospital at least once. We matched
HZ patients and non-HZ control subjects 1:4 by frequency of age, gender, and index date. The
index date was the date on which herpes zoster was diagnosed. Non-herpes zoster subjects
were selected as controls from the index date for matching with HZ patients.

Coexisting medical illnesses were identified as potential confounders by ICD-9-CM diag-
nostic codes, including diabetes mellitus (ICD-9-CM code 250), stroke (ICD-9-CM 430–438),
coronary artery disease (ICD-9-CM 414), chronic kidney disease (ICD-9-CM code 585), diabe-
tes with peripheral circulatory disorders (ICD-9-CM 250.7), diabetes with renal manifestations
(ICD-9-CM 250.4), diabetes with ophthalmic manifestations (ICD-9-CM 250.5), and diabetes
with neurological manifestations (250.6). Furthermore, we also recorded information about
prescribed anti-diabetic agents according to the anatomic therapeutic chemical [ATC] classifi-
cation system. Drugs included thiazolidinedione (TZD): rosiglitazone (A10BG02), pioglitazone
(A10BG03) and metformin (A10BA02), as well as sulfonylureas (A10BB), alpha glucosidase
inhibitors (A10BF) and insulin (A10A).
Statistical analysis

Differences between the HZ group and non-HZ group were compared using a Chi-square test based on the social and demographic characteristics as well as underlying comorbidities. A univariate logistic regression model was used to compare the risk of HZ with baseline characteristics as shown by odds ratio (OR) with a 95% confidence interval (CI). In addition, multivariate logistic regression was performed to estimate the associations among complications, comorbidities, drugs used, DM duration and the risk of HZ infection in DM patients. A two-tailed p value of <0.05 was considered statistically significant. All statistical analyses were performed using the SAS statistical software (version 9.3 for Windows; SAS Institute, Inc., Cary, NC, USA).

Results

From 2005 to 2011, a total of 25,345 newly diagnosed patients with herpes zoster were enrolled in this study in a 1:4 ratio with control patients without herpes zoster (n = 101,380) (Fig 1). Patients with DM were associated with a 24% increase in the risk of HZ as compared to those without diabetes (OR = 1.24, 95% CI = 1.19–1.28, p<0.001, Table 1). The average incidence of HZ from 2005~2011 was estimated at 3.6 cases per 1000 PY, with the highest rate in patients >70 years old (9.53 cases per 1000 PY), and the lowest rate in those <30 years old (1.53 cases per 1000 PY). Age-stratified analysis revealed a higher risk for HZ in all age groups with the highest risk in patients <30 years old (OR = 1.54, 95% CI = 1.03–2.30, p<0.05) and the lowest risk in those >70 years old (OR = 1.16, 95% CI = 1.09–1.24, p<0.001). Both male and female diabetic patients appeared to have an increased risk of developing herpes zoster compared to those without diabetes, as shown in women (OR = 1.23, 95% CI: 1.17–1.29, p<0.001) and in men (OR = 1.25, 95% CI = 1.19–1.32, p<0.001), respectively.

Results of multivariate logistic regression analysis of the correlation between comorbidities and risk of HZ among diabetic patients are shown in Table 2. After adjusting for age, gender,
DM duration and confounding factors, we found that diabetic patients comorbid with coronary artery disease (CAD) alone had a significantly higher risk of developing HZ than patients without CAD (21.2% vs. 18.5%, adjusted OR = 1.21, 95% CI = 1.12–1.31, p < 0.001). Regarding the combination of complications associated with the risk of HZ, diabetic patients comorbid with both CAD and microvascular diseases had the highest risk (OR = 1.32, 95% CI = 1.12–1.55, p < 0.001), as compared to those without CAD or microvascular diseases.

Diabetic patients who took anti-diabetic agents such as thiazolidinedione (TZD), alpha-glucosidase inhibitors or insulin had an increased risk of HZ as compared to those who did not take these agents (adjusted OR = 1.11, 1.02 and 2.1, respectively; p < 0.01–p < 0.001, Table 3). However, there was no significant difference between HZ patients and non-HZ patients who took metformin or sulfonylureas alone. Using logistic regression analysis to determine the risk

| Table 2. Association between comorbidities or diabetes-related complications and risk of herpes zoster among diabetic patients. |
|---------------------------------------------------------------|
| **Herpes Zoster (HZ)**                                      |
| **No (n = 17183)**                                          |
| **Yes (n = 5106)**                                          |
| **Variables**                                              |
| **n (%)**                                                   |
| **P-value‡**                                                |
| **cOR (95%CI)**                                             |
| **aOR (95%CI)**                                             |
| **Comorbidities**                                          |
| Stroke                                                     |
| No                                                         |
| 14941 (87.0)                                                |
| 4412 (86.4)                                                |
| 1.00 (reference)                                           |
| 1.00 (reference)                                           |
| Yes                                                        |
| 2242 (13.1)                                                |
| 694 (13.4)                                                 |
| 1.05 (0.95–1.15)                                           |
| 1.09 (0.99–1.19)                                           |
| CAD                                                        |
| No                                                         |
| 14001 (81.5)                                                |
| 4026 (78.9)                                                |
| 1.00 (reference)                                           |
| 1.00 (reference)                                           |
| Yes                                                        |
| 3182 (18.5)                                                |
| 1080 (21.2)                                                |
| 1.18 (1.09–1.28)***                                         |
| 1.21 (1.12–1.31)***                                         |
| DM with peripheral circulatory disorders                    |
| No                                                         |
| 16827 (97.9)                                               |
| 4980 (97.5)                                                |
| 1.00 (reference)                                           |
| 1.00 (reference)                                           |
| Yes                                                        |
| 356 (2.1)                                                  |
| 126 (2.5)                                                  |
| 1.20 (0.97–1.47)                                           |
| 1.21 (0.99–1.49)                                           |
| DM with nephropathy                                        |
| No                                                         |
| 16085 (93.6)                                               |
| 4770 (93.4)                                                |
| 1.00 (reference)                                           |
| 1.00 (reference)                                           |
| Yes                                                        |
| 1098 (6.4)                                                 |
| 336 (6.6)                                                  |
| 1.03 (0.91–1.17)                                           |
| 1.04 (0.92–1.18)                                           |
| DM with retinopathy                                        |
| No                                                         |
| 16702 (97.2)                                               |
| 4946 (96.9)                                                |
| 1.00 (reference)                                           |
| 1.00 (reference)                                           |
| Yes                                                        |
| 481 (2.8)                                                  |
| 160 (3.1)                                                  |
| 1.12 (0.94–1.35)                                           |
| 1.13 (0.94–1.35)                                           |
| DM with neuropathy                                         |
| No                                                         |
| 16116 (93.8)                                               |
| 4761 (93.2)                                                |
| 1.00 (reference)                                           |
| 1.00 (reference)                                           |
| Yes                                                        |
| 1067 (6.2)                                                 |
| 345 (6.8)                                                  |
| 1.09 (0.97–1.24)                                           |
| 1.10 (0.97–1.25)                                           |
| Coexisting with diabetes-related complications‡             |
| CAD (-)/microvascular disease (-)                          |
| 12056 (70.2)                                               |
| 3423 (67.0)                                                |
| 1.00 (reference)                                           |
| 1.00 (reference)                                           |
| CAD (-)/microvascular disease (+)                          |
| 1945 (11.3)                                                |
| 603 (11.8)                                                 |
| 1.09 (0.99–1.21)                                           |
| 1.10 (1.00–1.22)                                           |
| CAD (+)/microvascular disease (-)                          |
| 2575 (15.0)                                                |
| 859 (16.8)                                                 |
| 1.18 (1.08–1.28)***                                         |
| 1.21 (1.11–1.32)***                                         |
| CAD (+)/microvascular disease (+)                          |
| 607 (3.5)                                                  |
| 221 (4.3)                                                  |
| 1.28 (1.09–1.50)*                                          |
| 1.32 (1.13–1.55)**                                         |

CAD: coronary artery disease; DM: diabetes mellitus; cOR: crude odds ratio; aOR: adjusted odds ratio, adjusted for age, gender, and DM duration
* p < 0.05
** p < 0.01
*** p < 0.001
‡ p-value of Chi-square test
† Test for a trend cross variable of a combination of complications

doi:10.1371/journal.pone.0146750.002
of HZ in diabetic patients who received different anti-diabetic drugs, we found a significantly higher risk of developing HZ in patients who received insulin therapy or insulin combined with other drugs than those treated with metformin or SU treatment alone (OR = 1.25, 95% CI = 1.11–1.41, p < 0.001).

### Discussion

The results of the present study demonstrated that there was an increased risk of HZ in patients comorbid with both DM and CAD as well as diabetes-related microvascular disorders. In addition, diabetic patients who received insulin alone or in combination with other anti-diabetic agents had a significantly higher risk of HZ than those receiving monotherapy.

The incidence of HZ in Taiwan is comparable with that cited in global reports, varying from 1.2–4.9 cases per 1000 PY. In the study by Jih et al. [12], the incidence of HZ was 4.89 cases per 1000 PY as compared to 3.62 cases per 1000 PY in the present study. This discrepancy may be attributable to the difference in the inclusion criteria between these studies. Our enrollment criteria were considerably stricter because we required patients to have at least two outpatient visits or one inpatient admission for treatment. In the study by Jih et al., patients who had only

| Table 3. Association between anti-diabetic agents and risk of herpes zoster among diabetic patients. |
|-------------------------------------------------|---------------------------------|---------------|------------|--------------|-------------------|
| Anti-diabetic Agents                            | Herpes Zoster (HZ)              |                |            | P-value†     | cOR (95%CI)       | aOR (95%CI)       |
|                                                | No (n = 17,183)                 | Yes (n = 5,106) |            |              |                   |                   |
| Metformin                                       | n (%)                          | n (%)          |            |              |                   |                   |
| No                                              | 8690 (50.6)                    | 2516 (49.3)    | 1.00       | (reference)  | 1.00 (reference)  |                   |
| Yes                                             | 8493 (49.4)                    | 2590 (50.7)    | 1.05       | (0.99–1.12)  | 1.05 (0.99–1.12)  |                   |
| Sulfonylureas                                    | 0.302                          |                |            |              |                   |                   |
| No                                              | 9096 (52.9)                    | 2661 (52.1)    | 1.00       | (reference)  | 1.00 (reference)  |                   |
| Yes                                             | 8087 (47.1)                    | 2445 (47.9)    | 1.03       | (0.97–1.10)  | 1.03 (0.97–1.10)  |                   |
| Thiazolidinedione                                | 0.010                          |                |            |              |                   |                   |
| No                                              | 14688 (85.5)                   | 4290 (84.0)    | 1.00       | (reference)  | 1.00 (reference)  |                   |
| Yes                                             | 2495 (14.5)                    | 816 (16.0)     | 1.12       | (1.03–1.22)**| 1.11 (1.02–1.21)*|                   |
| Alpha glucosidase inhibitors                     | 0.005                          |                |            |              |                   |                   |
| No                                              | 14753 (85.9)                   | 4303 (84.3)    | 1.00       | (reference)  | 1.00 (reference)  |                   |
| Yes                                             | 2430 (14.1)                    | 803 (15.7)     | 1.13       | (1.04–1.24)**| 1.14 (1.04–1.24)**|                   |
| Insulin                                         | <0.001                         |                |            |              |                   |                   |
| No                                              | 13951 (81.2)                   | 4023 (78.8)    | 1.00       | (reference)  | 1.00 (reference)  |                   |
| Yes                                             | 3232 (18.8)                    | 1083 (21.2)    | 1.16       | (1.08–1.26)**| 1.18 (1.09–1.27)**|                   |
| Anti-diabetic agents in combination‡            | <0.001                         |                |            |              |                   |                   |
| Metformin only or Sulfonylureas only             | 1817 (10.6)                    | 488 (9.6)      | 1.00       | (reference)  | 1.00 (reference)  |                   |
| Metformin + others or Sulfonylureas + others     | 12134 (70.6)                   | 3535 (69.2)    | 1.09       | (0.98–1.21)  | 1.08 (0.97–1.20)  |                   |
| Insulin only or Insulin+others                   | 3232 (18.8)                    | 1083 (21.2)    | 1.25       | (1.11–1.41)**| 1.25 (1.11–1.42)**|                   |

cOR: crude odds ratio; aOR: adjusted odds ratio. Adjusted for age, gender, and DM duration.

* p<0.05
** p<0.01
*** p<0.001
† p-value of Chi-square test
‡ Others include TZD and alpha glucosidase inhibitors

doi:10.1371/journal.pone.0146750.t003
one outpatient visit or a single inpatient admission were enrolled. Jih et al. used a retrospective cohort design, which included inpatient and outpatient claims data, and the authors followed up patients from 2000 to 2006. Our design, however, was a case-control study in which patients were retrospectively assessed from 2005 to 2011 for the presence or absence of HZ infection. Though retrospective cohort and case-control designs have both advantages and disadvantages in answering observational questions, the reliability of both types of studies is similar in providing strength of evidence [13].

Due to a decline in CMI in diabetic patients, the results of our study were in line with those of previous population-based studies, in which diabetic patients were more susceptible to HZ (OR = 1.24) than non-diabetic patients. Guignard et al. [5] found that type 2 DM was associated with an enhanced risk of HZ with a hazard ratio of 1.97. In a nested case-control study, Heymann et al. also demonstrated an increased risk of HZ with an odds ratio of 1.53 in diabetic patients [14]. However, the result of our study demonstrated a lower risk of HZ in comparison to Guignard’s and Heymann’s studies. Three major factors may contribute to this inconsistency. The first direct factor is the racial differences in the occurrence of herpes zoster among studies conducted in different countries. There are evidences showing that non-white had a significantly lower risk of developing herpes zoster than white [15,16]. The second contributory factor is the difference in health insurance among these countries. Our health insurance is a nationwide healthcare system which included all socioeconomic status in Taiwan with 99% population coverage, which can be a reliable representative of diseases with diagnosis and follow-up. The last critical factor is the difference in age selection. In our study, we only selected adult patients while they included all ages. It is thus possible that if adolescent diabetic patients, mainly Type 1 DM, were not included as occurred in our study, a diminished risk or OR of HZ occurrence was expected. Therefore, the risk of developing HZ in diabetic patients may vary substantially depending on many risk factors, especially in countries where races, population age, weather and health insurance are essentially different.

Similar to the primary immune response to VZV in children, an expansion of antigen-specific memory CD4+ T cells including CD45RA and CD27 cells is triggered in response to the re-exposure of HZ patients to varicella infection. In addition, there was a concomitant change in cytotoxic CD8+ T cells and natural killer cells in the peripheral blood, accompanied by a release of cytokines such as interferon-γ, tumor necrosis factor-α, and interleukin-2 [17]. The imbalance of T cell-mediated immunity in patients predisposed to varicella infection may be attributable to the dysfunction of T lymphocytes involving both VZV-specific memory CD4+ and cytotoxic CD8+ T cells [17, 18]. In association with a compromised CMI, the study by Pedicino et al. demonstrated a strong relationship between DM and the imbalance of T-cell homeostasis involving the expansion of CD4+CD28null T-cells and the reduction in CD4+CD25+Foxp3+ regulatory T-cells [19].

Patients with cardiovascular diseases such as coronary artery disease (CAD) are associated with a compromised adaptive immune response, not only in CD4+ T cells but also in CD8+ T cells [20, 21]. After the first episode of acute coronary syndrome, diabetic patients are usually found to be associated with the expansion of CD4+CD28null T-cells, which are manifested as poor glycemic control with worse outcome [22]. In addition, one year after an acute cardiac event, patients with CAD demonstrated an accelerated immunosenescence with an increase in the proportion of CD4+CD28null and CD8+CD28 null cells [23]. Joesoef et al. reported that the risk of HZ would be increased if patients had coexisting prevalent chronic disorders, such as CAD, DM, hyperlipidemia or hypertension, though most causes of HZ were largely undetermined [10]. Our results further demonstrated that diabetic patients had an escalated risk of HZ (aOR = 1.32) when they were comorbid with CAD or had CAD in combination with other diabetic-related microvascular disorders. There is evidence showing that varicella-zoster virus
infection can lead to endothelial dysfunction as the result of increased inflammation with immune-mediated vasculitis [24, 25]. Studies have also demonstrated that patients afflicted with herpes zoster had an increased risk of developing myocardial infarction and stroke as well as other microvascular diseases. It is speculated that when T cell-mediated immunity declined as occurred in diabetic patients, the varicella-zoster virus infection may possibly lead to chronic endothelial inflammation with atherosclerotic plaque-formation of the arterial walls. Therefore, it is most likely that the escalated risk of HZ in patients comorbid with both DM and CAD is due to compromised T cell-mediated immunity as well as immune-mediated vasculopathy secondary to varicella-zoster virus infection. However, our study had an inherent limitation in which the event sequence of DM and CAD could not be identified from our claims database. It is argued that CAD may be an isolated comorbid disorder that accompanies DM or a progressive vascular complication related to diabetes.

Several studies demonstrated an enhanced release of pro-inflammatory cytokines triggered by long-term stress-induced hyperglycemia, which elicited insulin resistance and affected the function of innate immunity [26]. Adaptive immunity was also impaired by hyperglycemia, which increased the risk of infections and mortality. Therefore, tight glycemic control during hyperglycemic conditions was beneficial to the maintenance of the CMI in the host [27]. Metformin and sulphonylureas are still the first-line oral agents used for hyperglycemia in patients with type 2 diabetes mellitus because they are inexpensive and have fewer adverse effects. It is widely understood that many commonly used anti-diabetic agents exert glucose-lowering effects by different mechanisms of action on glucose metabolism and pancreatic insulin secretion. However, accumulating evidence has demonstrated that these anti-diabetic agents can exert significant anti-inflammatory effects to diminish overall diabetes-related complications, which are independent to its glucose-lowering efficacy. Thiazolidinediones (TZDs), metformin and insulin have demonstrated greater anti-inflammatory effects than sulphonylureas and alpha-glucosidase inhibitors [28]. Compared with TZDs or insulin, which increased the risk of HZ, the present study showed that metformin and sulphonylureas did not increase the risk of HZ in diabetic patients. The corollary to this notion is that patients given monotherapy such as metformin or sulphonylureas for hyperglycemia may be at the initial stage of diabetes in which their symptoms are relatively mild with minimal abnormal biochemical changes. However, when targeted monotherapy fails to yield a better glycemic control during the progression of the disease, combination therapy with stronger hypoglycemic agents is highly recommended. Therefore, we need to conduct further studies to determine whether tight glycemic control can be attained in our diabetic patients treated with anti-diabetic agents.

Limitations
The main limitation of the present study is that the Taiwan NHIRD does not provide temporal blood glucose levels, HbA1c levels or dosages of anti-diabetic drugs. The lack of this data may have led to underestimation of the number of patients with mild symptoms who did not seek medical treatment, although such underestimation should remain stable over time.

Conclusions
In summary, the present study demonstrated that there was an escalated risk of HZ occurrence in diabetic patients comorbid with coronary artery disease and associated microvascular disorders. In addition, a higher risk of HZ was significantly demonstrated in diabetic patients who were given insulin alone or in combination with other anti-diabetic agents compared to those who received monotherapy. Further studies with cohort design are necessary to clarify the
effect of vaccination on the risk of developing herpes zoster in these groups of patients in Taiwan.

Author Contributions
Conceived and designed the experiments: PWL CCK HL CJH. Performed the experiments: PWL CCK HL CJH. Analyzed the data: CHL. Wrote the paper: PWL CCK HL CJH WHHS DYC. Literature review: PWL CCK CHL HCL DYC.

References
1. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996; 9: 361–381 PMID: 8809466
2. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013; 369: 255–263. doi: 10.1056/NEJMc1302674 PMID: 23863052
3. Lungo U, Annunziato PW, Gershon A, Staugaitis SM, Josefsen D, LaRussa P, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci USA. 1995; 92(24): 10980–10984. PMID: 7479921
4. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014; 4: e004833. doi: 10.1136/bmjopen-2014-004833 PMID: 24916088
5. Lungo U, Annunziato PW, Gershon A, Staugaitis SM, Josefsen D, LaRussa P, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci USA. 1995; 92(24): 10980–10984. PMID: 7479921
6. Guignard AP, Greenberg M, Lu C, Rosillon D, Vannappagari V. Risk of herpes zoster among diabetics: a matched cohort study in a US insurance claim database before introduction of vaccination, 1997–2006. Infection. 2014; 42: 729–735. doi: 10.1007/s15100-014-0645-x PMID: 24937980
7. Asia Pacific Cohort Studies Collaboration. Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region. Diabetologia. 2007; 50: 2289–2297. PMID: 17909878
8. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979; 59: 8–13. PMID: 758126
9. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987; 3: 463–524. PMID: 3552530
10. Joesoef RM, Harpaz R, Leung J, Bialek SR. Chronic medical conditions as risk factors for herpes zoster. Mayo Clin Proc. 2012; 87: 961–967. doi: 10.1016/j.mayocp.2012.05.021 PMID: 23036671
11. Breuer J, Pacou M, Gauthier A, Brown M. Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the UK. Neurology. 2014; 82: 206–212. doi: 10.1212/WNL.000000000000038 PMID: 24384645
12. Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol. 2009; 89: 612–616. doi: 10.2340/00015555-0729 PMID: 19997693
13. Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg. 2010; 126: 2234–2242. doi: 10.1097/PRS.0b013e3181f44aba PMID: 20697313
14. Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection. 2008; 36: 226–230. doi: 10.1007/s15100-007-6347-x PMID: 18454342
15. Nagasako EM, Johnson RW, Griffin DR, Elpern DJ, Dworkin RH Geographic and racial aspects of herpes zoster. J Med Virol. 2003; 70: S20–23. PMID: 12627482
16. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004; 4: 26–33 PMID: 14720565
17. Vossen MT, Gent MR, Weel JF, de Jong MD, van Lier RA, Kuijpers TW. Development of virus-specific CD4+ T cells on reexposure to varicella-zoster virus. J Infect Dis. 2004; 190: 72–82. PMID: 15195245
18. Park HB, Kim KC, Park JH, Kang TY, Lee HS, Kim TH, et al. Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus. J Rheumatol. 2004; 31: 2151–2155. PMID: 15517626
19. Pedicino D, Liuzzo G, Trotta F, Giglio AF, Giubilato S, Martini F, et al. Adaptive immunity, inflammation, and cardiovascular complications in type 1 and type 2 diabetes mellitus. J Diabetes Res. 2013; 184258. doi: 10.1155/2013/184258 PMID: 23762872
20. Pedicino D, Giglio AF, Galiffa VA, Trotta F, Liuzzo G. Type 2 diabetes, immunity and cardiovascular risk: a complex relationship. In: Oluwafemi O, ed. Pathophysiology and Complications of Diabetes Mellitus. InTech. 2012. 45–70.

21. Legein B, Temmerman L, Biesen EA, Lutgens E. Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci. 2013; 70: 3847–3869. doi: 10.1007/s00018-013-1289-1 PMID: 23430000

22. Giubilato S, Liuzzo G, Brugaletta S, Pitocco D, Graziani F, Smaldone C, et al. Expansion of CD4+CD28 null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus. Eur Heart J. 2011; 32: 1214–1226. doi: 10.1093/eurheartj/ehq499 PMID: 21217142

23. Backteman K. T cells and NK cells in coronary artery disease: longitudinal and methodological studies in humans. Linköping: Linköping University Electronic Press; 2014. Linköping University Medical Dissertations, 1409.

24. Nagel MA. Varicella zoster virus vasculopathy: clinical features and pathogenesis. J Neurovirol. 2014; 20: 157–163. doi: 10.1007/s13365-013-0183-9 PMID: 23918503

25. Jacob HS, Visser M, Key NS et al. Herpes virus infection of the endothelium: new insights into atherosclerosis. Trans Am Clin Climatol Assoc 1992; 103:95–104. PMID: 1329303

26. Xiu F, Stanojcic M. Stress hyperglycemia, insulin treatment, and innate immune cells. Int J Endocrinol. 2014; 2014: 486403. doi: 10.1155/2014/486403 PMID: 24899891

27. Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007; 23: 3–13. PMID: 16960917

28. Scheen AJ, Esser N, Paquot N. Antidiabetic agents: potential anti-inflammatory activity beyond glucose control. Diabetes Metab. 2015: 02.003.